Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Phase 3

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: without concurrent cisplatin chemotherapy
Drug: with concurrent cisplatin chemotherapy

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 476

Registration Number: NCT06095167

Locations: 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China

Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma

Phase 2

Recruiting

Conditions: Neuroendocrine Carcinoma of the Bladder
Bladder Cancer

Interventions: Drug: Adebrelimab
Drug: Etoposide
Drug: Cisplatin
Procedure: Radical Cystectomy

First Posted Date: 2023-10-19

Last Posted Date: 2025-01-03

Lead Sponsor: RenJi Hospital

Target Recruit Count: 22

Registration Number: NCT06091124

Locations: 🇨🇳
Ren Ji Hospital, Shanghai, Shanghai, China

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Phase 2

Withdrawn

Conditions: Oropharyngeal Squamous Cell Carcinoma
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Head and Neck Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma
Oral Cavity Squamous Cell Carcinoma
Stage IV Laryngeal Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Chest Radiography
Drug: Cisplatin
Procedure: Computed Tomography
Radiation: Image Guided Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Xevinapant

First Posted Date: 2023-10-16

Last Posted Date: 2024-07-25

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Registration Number: NCT06084845

Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Penpulimab injection
Drug: cisplatin
Drug: albumin-paclitaxel

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Target Recruit Count: 72

Registration Number: NCT06081673

Locations: 🇨🇳
Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: BI 764532
Drug: Etoposide
Drug: Carboplatin
Drug: Cisplatin
Drug: Durvalumab
Drug: Atezolizumab

First Posted Date: 2023-10-11

Last Posted Date: 2025-01-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06077500

Locations: 🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States
🇧🇪
Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷
INS Bergonie, Bordeaux, France

and more 11 locations

Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

Phase 2

Not yet recruiting

Conditions: Endometrial Cancer
Endometrial Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel

First Posted Date: 2023-10-04

Last Posted Date: 2024-01-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 45

Registration Number: NCT06066216

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Phase 2

Recruiting

Conditions: Stage IV Nasopharyngeal Carcinoma AJCC v8
Stage II Nasopharyngeal Carcinoma AJCC v8
Stage III Nasopharyngeal Carcinoma AJCC v8

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Chest Radiography
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Echocardiography
Other: Electronic Health Record Review
Other: Fluciclovine F18
Drug: Gemcitabine
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Biological: Nivolumab
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy
Procedure: X-Ray Imaging

First Posted Date: 2023-10-03

Last Posted Date: 2024-12-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT06064097

Locations: 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 40 locations

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Phase 2

Recruiting

Conditions: Peritoneal Mesothelioma
Mesothelioma
Malignant Peritoneal Mesothelioma
Malignant Mesothelioma
Mesothelioma, Malignant

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2023-09-28

Last Posted Date: 2024-10-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT06057935

Locations: 🇺🇸
University of Chicago (Data Collection Only), Chicago, Illinois, United States
🇺🇸
University of Michigan (Data Collection Only), Ann Arbor, Michigan, United States
🇺🇸
University of Nebraska (Data collection only), Omaha, Nebraska, United States

and more 10 locations

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Phase 1

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Xevinapant
Drug: Cisplatin
Radiation: intensity-modulated radiation therapy (IMRT)

First Posted Date: 2023-09-28

Last Posted Date: 2024-07-18

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 18

Registration Number: NCT06056310

Locations: 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸
Montefiore Medical Center PRIME, Bronx, New York, United States
🇧🇪
Universitair Ziekenhuis Gent - Medical Oncology, Gent, Belgium

and more 20 locations

Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC

Phase 2

Recruiting

Conditions: Locally Advanced Cervical Cancer

Interventions: Drug: Zimberelimab
Drug: Albumin-bound Paclitaxel
Drug: Cisplatin

First Posted Date: 2023-09-28

Last Posted Date: 2023-09-28

Lead Sponsor: Tang-Du Hospital

Target Recruit Count: 20

Registration Number: NCT06055738

Locations: 🇨🇳
Hongxi Zhao, Xi'an, Shaanxi, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy